Research funding and grants

1. Durvalumab after chemoradiation for stage III non-small cell lung cancer – the DART-study. Helse Sør-Øst, Åpen Prosjektstøtte, 2018.
2. Durvalumab after chemoradiation for stage III non-small cell lung cancer – the DART-study. Helse Sør-Øst, KlinBeForsk, 2019. 
3. Malignant mesothelioma treated with immune checkpoint inhibitors with or without cancer vaccine (the NIPU-study), Helse Sør-Øst, 2019. 
4. Ekspertgruppe for lungekreft, Kreftforeningen, 2020. 
5. Malignant mesothelioma treated with immune checkpoint inhibitors with or without cancer vaccine (the NIPU-study), Helse Sør-Øst, Åpen prosjektstøtte,) 2021. 
6. Immunotherapy combined with extensive radiotherapy for the treatment of stage IV non-small cell lung cancer (COM-IT-2), Kreftforeningen, 2022. 
7. Precision medicine in computational pathology, post.doc. Astra Zeneca. 2022. 

 Clinical trials have received unrestricted grants/drugs from Astra Zeneca, BMS, Ultimovacs and GSK